In another study from China, the researchers found a significant increase in serum FGL-1 in DCM patients compared to healthy and T2DM patients, suggesting the potential of FGL-1 for early diagnosis of DCM and as its therapeutic target (Liu et al., 2024). This evidence concerns the gene FGL1 and familial dilated cardiomyopathy.